Visgenx to present at the American Society of Gene and Cell Therapy 2023 Annual Meeting
Poster presentation covers data on VGX-0111, the Company’s gene therapy candidate for Dry Age-related Macular Degeneration (AMD), an aging related disorder and a leading cause of vision loss SAN DIEGO, May 15, 2023 /PRNewswire/ — Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced that the Company will … Read more